D J Kereiakes
Overview
Explore the profile of D J Kereiakes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
1536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Young J, Kereiakes D
Am Heart J
. 2000 Dec;
140(6 Suppl):S148-53.
PMID: 11100009
Adjunctive blockade of the platelet glycoprotein (GP) IIb/IIIa receptor during either percutaneous coronary intervention (PCI) or for patients who present with non-ST segment elevation acute coronary syndromes has demonstrated efficacy...
22.
Kereiakes D, Obenchain R, Barber B, Smith A, McDonald M, Broderick T, et al.
Am Heart J
. 2000 Sep;
140(4):603-10.
PMID: 11011333
Background: Placebo-controlled randomized trials of platelet glycoprotein (GP) IIb/IIIa blockade during percutaneous coronary intervention have demonstrated efficacy of these agents for reducing the risk of periprocedural ischemic events. However, cost-effectiveness...
23.
Gurbel P, Kereiakes D, Serebruany V
J Thromb Thrombolysis
. 2000 Aug;
10(1):15-22.
PMID: 10947910
It has been reported that platelet expression and plasma levels of soluble P-selectin are increased in patients with unstable coronary artery syndromes. However, the origin of soluble P-selectin remains unknown....
24.
Harrington R, Armstrong P, Graffagnino C, Van de Werf F, Kereiakes D, Sigmon K, et al.
Circulation
. 2000 Aug;
102(7):728-35.
PMID: 10942739
Background: Antiplatelet therapy is the mainstay of the treatment and secondary prevention of cardiovascular and cerebrovascular ischemic events. We assessed the safety, tolerability, and pharmacodynamics of lotrafiban, an oral platelet...
25.
Kereiakes D, Smith S, Jacobs A, Kern M, Faxon D
J Am Coll Cardiol
. 2000 Jul;
36(1):299-303.
PMID: 10898451
No abstract available.
26.
Kereiakes D, Berkowitz S, Lincoff A, Tcheng J, Wolski K, ACHENBACH R, et al.
Am Heart J
. 2000 Jun;
140(1):74-80.
PMID: 10874266
Background: Thrombocytopenia is infrequently associated with abciximab therapy but may contribute to hemorrhagic risk. Factors associated with development of thrombocytopenia, the role of weight-adjustment in concomitant heparin administration, and clinical...
27.
Gurbel P, Kereiakes D, Atar D, Serebruany V
Scand Cardiovasc J
. 2000 May;
34(1):53-8.
PMID: 10816061
The early identification of patients with heightened platelet activity for aggressive antiplatelet regimens represents a critical clinical issue in acute myocardial infarction (AMI) therapy. We sought to determine whether the...
28.
Davidson C, Laskey W, Hermiller J, Harrison J, Matthai Jr W, Vlietstra R, et al.
Circulation
. 2000 May;
101(18):2172-7.
PMID: 10801758
Background: Previous in vitro and in vivo studies have suggested an association between thrombus-related events and type of contrast media. Low osmolar contrast agents appear to improve the safety of...
29.
Kereiakes D, Runyon J, Broderick T, Shimshak T
Am J Cardiol
. 2000 May;
85(8A):23C-31C.
PMID: 10793177
Platelet glycoprotein (GP) IIb/IIIa receptor blockade improves clinical outcomes after percutaneous coronary intervention (PCI) and for patients who present with non-ST-segment elevation acute coronary syndromes. Although this class of therapeutic...
30.
Tramuta D, Kereiakes D, Dippel E, Lengerich R, Broderick T, Abbottsmith C, et al.
J Invasive Cardiol
. 2000 Apr;
12 Suppl C:3C-6C.
PMID: 10762860
No abstract available.